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2802Objective: The management of coexistent tricuspid regurgitation in patients with mitral regurgitation remains
controversial. We sought to define the incidence and natural history of coexistent tricuspid regurgitation in
patients undergoing isolated mitral surgery for degenerative mitral regurgitation, as well as the effect of late
secondary tricuspid regurgitation on cardiovascular symptom burden and survival.
Methods: To minimize confounding, analysis was limited to 495 consecutive patients who underwent isolated
mitral surgery for degenerative mitral valve disease between 2002 and 2011. Patients with coexistent severe
tricuspid regurgitation were excluded because such patients typically undergo concomitant tricuspid
intervention.
Results: Grade 1 to 3 coexistent tricuspid regurgitation was present in 215 patients (43%) preoperatively.
Actuarial freedom from grade 3 to 4 tricuspid regurgitation 1, 5, and 9 years after surgery was 100%  0%,
90% 2%, and 64% 7%, respectively. Older age (P<.001) and grade of preoperative tricuspid regurgitation
(P ¼ .006) independently predicted postoperative progression of tricuspid regurgitation on multivariable
analysis. However, when limited to patients with mild or absent tricuspid regurgitation, indexed tricuspid
annular diameter was the only significant risk factor for late tricuspid regurgitation (P ¼ .04). New York Heart
Association functional class and long-term survival did not worsen with development of late secondary tricuspid
regurgitation (P ¼ .4 and P ¼ .6, respectively). However, right ventricular dysfunction was significantly more
common in patients with more severe late tricuspid regurgitation (P ¼ .007).
Conclusions: Despite durable correction of degenerative mitral regurgitation, less than severe tricuspid
regurgitation is likely to progress after surgery if uncorrected. Given the low incremental risk of tricuspid
annuloplasty, a more aggressive strategy of concomitant tricuspid repair may be warranted. (J Thorac Cardio-
vasc Surg 2014;148:2802-10)See related commentary on pages 2810-2.The contemporary management of coexistent tricuspid
regurgitation (TR) in patients with mitral regurgitation
(MR) remains controversial. As such, the frequency of
tricuspid valve repair varies significantly.1-3 Early data that
surgical correction of mitral valve disease secondarily
alleviates functional TR by improving left heart
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The Journal of Thoracic and Cardiovascular Surstrain have led many physicians to manage coexistent
TR conservatively.2,4,5 However advocates for a more
aggressive surgical strategy maintain that the development
of late significant TR after isolated mitral valve surgery is
not uncommon,6-8 and untreated TR is independently
associated with significantly worse cardiovascular symptom
burden and survival.9 Furthermore, late surgical intervention
for recurrent TR is often prohibitively dangerous,10,11
whereas concomitant tricuspid annuloplasty presents lower
risk and durably prevents recurrent TR.12-15 As such, a
prophylactic strategy of routine concomitant tricuspid valve
repair has recently been proposed.3
Although generally absent from society guidelines, disease
etiology is paramount inmanagingMR andmay significantly
influence progression of functional TR. Because increasing
evidence supports early surgical repair of patients with severe
degenerativeMRbefore the development of adverse sequelae
of longstanding disease16 (eg, ventricular remodeling and
dysfunction, pulmonary hypertension, and atrial fibrillation),
perhaps this patient population is less likely to develop late
significant TR if left untreated. Furthermore, guidelines17,18
have become increasingly aggressive with regard to
concomitant tricuspid valve repair despite a large report of
patients with degenerative MR demonstrating thatgery c December 2014
Abbreviations and Acronyms
MR ¼ mitral regurgitation
NYHA ¼ New York Heart Association
TR ¼ tricuspid regurgitation
Goldstone et al Acquired Cardiovascular Disease
A
C
Dprogression of nonsevere TR is unlikely in this population.2
Clearly, more data are needed to better inform the clinical de-
cisionmaking surrounding coexistent TR. Thus, we sought to
define the incidence and natural history of coexistent TR in
patients undergoing isolatedmitral valve surgery for degener-
ative mitral valve disease, as well as determine the influence
of late secondary TR on cardiovascular symptom burden
and survival.
PATIENTS AND METHODS
Between 2002 and 2011, 4241 patients underwent mitral valve surgery
at our institution. Isolated mitral valve surgery, defined as any mitral valve
procedure performed in the absence of a major concomitant procedure
(eg, coronary bypass, other valve surgery, or aortic surgery) was performed
in 1011 patients. To minimize confounding, analysis was limited to 495
consecutive patients who underwent isolated mitral valve surgery for
chronic severe MR secondary to mitral valve prolapse. Patients with
preoperative coexistent severe TR were excluded. Also excluded were
patients with primary pulmonary disease or structural tricuspid valve
abnormalities. Data were in part retrieved from the University of
Pennsylvania’s prospective Society of Thoracic Surgeons registry and
partially obtained from each patient’s medical record. These data were
approved for use in research by the University of Pennsylvania Institutional
Review Board with a waiver of patient consent.
All patients underwent mitral valve surgery for severe MR due to leaflet
prolapse. The techniques used during mitral valve surgery have been pre-
viously described.19-21 Posterior leaflet prolapse was typically corrected
with triangular or quadrangular resection of the prolapsed segment, or
nonresectional leaflet remodeling. Anterior leaflet prolapse was
characteristically repaired with polytetrafluoroethylene neochords. All
repairs were supplemented with a circumferential or partial ring
annuloplasty sized to the surface area of the anterior leaflet.
For each patient, pre- and postoperative TR was graded on a standard,
semiquantitative 0 to 4 scale: grade 0 ¼ none, grade 1 ¼ trivial, grade
2 ¼ mild, grade 3 ¼ moderate, and grade 4 ¼ severe. Postdischarge
transthoracic echocardiograms were available for 362 patients (73%),
with a median follow-up of 3.4 years (minimum 18 days, maximum
11.1 years). Postdischarge echocardiograms were interpreted by the
referring cardiologist. Clinical follow-up data were collected from
postoperative visit data and records from referring cardiologists (median
follow-up was 4.5 years with an interquartile range of 3.2-6.3 years).
A subgroup analysis of 127 patients (25%) was conducted to elucidate
the prognostic value of tricuspid annular dilation. Using intraoperative
transesophageal echocardiograms, the tricuspid valve annulus was
measured from the midesophageal 4-chamber and short axis views before
mitral valve intervention. Measurements were obtained at end diastole and
end systole by a single, level-III trained echocardiographer.
Continuous variables are expressed as the mean  standard deviation
and categorical variables are presented as proportions. Comorbid diagnoses
and perioperative outcome variables adhere to the definitions of the Society
of Thoracic Surgeons. Changes in coexistent TR from preoperative values
to pre- and postbypass values were compared using the Wilcoxon
signed-rank test. Differences in tricuspid annular diameter were compared
with 1-way analysis of variance tests. Cox regression models were used to
identify predictors of TR progression during follow-up. The multivariableThe Journal of Thoracic and Carmodel considered all variables found to be significant on univariate
analysis (P<.05) in a stepwise fashion (forward and backward selection
yielded equivalent models). Survival and cardiovascular symptom burden
analyses were performed using Kaplan-Meier analysis with log-rank tests.
All tests were 2-tailed. The statistical analysis was performed using
IBM-SPSS Statistics for Macintosh, version 20.0 (IBM-SPSS, Inc,
Armonk, NY).
RESULTS
A total of 495 patients who underwent isolated mitral
valve surgery met the inclusion criteria for the study.
All patients underwent mitral valve repair. Baseline
demographics and comorbidity profiles are summarized in
Table 1. Preoperatively, nearly one-third of patients were
asymptomatic based on New York Heart Association
(NYHA) functional class assessment (n ¼ 116; 32.3%)
and 56 patients (11.3%) had a history of atrial fibrillation
or flutter. The majority of patients had no evidence of
coexistent TR on preoperative echocardiography (n ¼ 280;
56.6%). Although 146 patients (29.5%) had grade 2 coexis-
tent TR or higher on preoperative echocardiography, none
was deemed by the attending surgeon to require concomitant
intervention at the time of mitral valve surgery.
Changes in Coexistent TR
We compared TR grade at preoperative and intraopera-
tive time points in the 39 patients with grade 3 preoperative
TR (Figure 1). Intraoperative grade of TR (pre- and
postcardiopulmonary bypass) was significantly lower than
preoperative TR grade. In fact, only 1 patient was found
to have grade 3 TR on intraoperative echocardiographic
assessment. Grade of TR did not significantly differ
between pre- and postcardiopulmonary bypass time points.
Applying Kaplan-Meier analysis to the overall cohort
revealed actuarial freedom from grade 3 or greater TR
at 1, 5, and 9 years after surgery was 100%  1%,
90%  2%, and 64%  7%, respectively. When stratified
by preoperative TR grade, patients with greater degrees of
coexistent TR demonstrated faster progression to
significant postoperative TR (P<.001) (Figure 2). During
the same time interval, freedom from recurrent grade 3
or greater MR at 1, 5, and 9 years after surgery was
99%  1%, 92%  2%, and 82%  5%, respectively.
One patient developed grade 4 MR during the study period
and 16 patients developed grade 3 MR, but severity of
recurrent MR was not found to be significantly associated
with progression of TR in univariate or multivariable
analyses. Out of 22 fixed-effect preoperative variables
examined in univariate analyses, 8 were found to be
significant predictors of TR progression during follow-up.
However only advanced age and preoperative TR grade
remained significant risk factors for progression of TR on
multivariable analysis (Table 2). It should be noted that
although preoperative atrial fibrillation failed to remain
significant in multivariable analysis, postoperative atrialdiovascular Surgery c Volume 148, Number 6 2803
TABLE 1. Demographics and risk profile of study population
(N ¼ 495)
Variable Value
Demographic
Age (y) 57.5  12.5
Female gender 174 (38.2)
Comorbidities
Atrial fibrillation 56 (11.3)
Renal failure 7 (1.4)
Hypertension 211 (42.6)
Chronic lung disease 41 (8.3)
Peripheral arterial disease 6 (1.2)
Cerebrovascular disease 15 (3.0)
Previous cardiac surgery 30 (6.1)
New York Heart Association functional class
I 160 (32.3)
II 262 (52.9)
III 68 (13.7)
IV 5 (1.0)
Mean pulmonary artery pressure (mm Hg) 21.5  8.9
Ejection fraction (%) 58.3  8.4
Tricuspid regurgitation grade
0 280 (56.6)
1 69 (13.9)
2 107 (21.6)
3 39 (7.9)
Tricuspid annular diameter (mm) 40.1  5.6
Indexed tricuspid annular diameter (mm/m2) 20.9  3.2
Leaflet prolapse
Posterior 371 (74.9)
Anterior 28 (5.7)
Bileaflet 96 (19.4)
Values for continuous variables are presented as means  standard deviation. Others
are presented as n (%).
FIGURE 1. Mean grade of tricuspid regurgitation (TR) significantly
decreases from preoperative value with the institution of cardiopulmonary
bypass in patients with grade 3 TR (N ¼ 39). *P<.001 compared with
preoperative value.
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both significant in univariate and multivariable analyses
(hazard ratio, 2.0; P ¼ .03) in addition to age and
preoperative TR grade.Tricuspid Annular Dilation and Late TR
Mean indexed tricuspid annular diameter increased with
increasing severity of preoperative TR (grade 0, 20.4  3.2
mm/m2; grade 1 and 2, 20.8 3.2mm/m2; and grade 3, 23.4
 2.5 mm/m2; P¼ .005). In fact, all but 1 patient with grade
3 preoperative TR had an indexed tricuspid annular diam-
eter greater than 21 cm/m2—the current recommended
threshold for repair. Although a significant predictor of
late TR on univariate analysis, indexed tricuspid annular
diameter failed to remain significant on multivariable
analysis (Table 2). However in patients with less than grade
3 preoperative TR, indexed tricuspid annular diameter was
the only independent risk factor for progression of TR
(hazard ratio, 6.3; P ¼ .04). Nonindexed tricuspid annular
diameter was not a significant predictor of late TR in
univariate or multivariable analyses.2804 The Journal of Thoracic and Cardiovascular SurBurden of Postoperative TR
Despite a 63%  14% freedom from grade 3 or greater
TR 10 years after mitral valve surgery, no patient underwent
late intervention on the tricuspid valve. Freedom from
NYHA functional class III or IV at 1, 5, and 9 years after
surgical correction of MR was 99%  1%, 97%  1%,
and 96%  2%, respectively. Furthermore, cardiovascular
symptom burden as assessed by NYHA functional class did
not significantly worsen with development of greater
degrees of late secondary TR (P ¼ .4). On the other
hand, freedom from moderate or greater right ventricular
dysfunction at 1, 5, and 9 years after surgery was 98% 
1%, 90%  3%, and 70%  9%, respectively, and right
ventricular dysfunction was significantly associated with
higher postoperative TR grade (P ¼ .007) (Figure 3).
There were no deaths before hospital discharge. Overall
survival 1, 5, and 10 years after surgery was 99%  1%,
97%  1%, and 96%  1%, respectively. Survival trends
did not significantly differ when stratified by development
of postoperative TR (P ¼ .6).DISCUSSION
The management of coexistent TR in patients with
chronic MR remains controversial. Although some advo-
cate that relief of left-sided valve dysfunction will durably
correct functional TR, society guidelines are becoming
increasingly aggressive with regard to the implementation
of concomitant tricuspid valve repair. Our results support
a more aggressive approach. By analyzing clinical and
echocardiographic data from a homogenous population of
patients undergoing isolated mitral valve surgery for
degenerative mitral valve disease, we found that postopera-
tive TR progression is not uncommon, and is associated
with worsening right ventricular function.
Coexistent TR is relatively common in patients referred
for chronic severe MR.2,12,22 Although early experiencegery c December 2014
FIGURE 2. Freedom from grade 3 or greater tricuspid regurgitation (TR) after isolated mitral valve surgery stratified by preoperative TR grade.
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is consistently improved with correction of left-sided valve
dysfunction,4,5 it was later realized that in select patients TR
may gradually worsen, resulting in debilitating right heart
failure requiring reoperation. Unfortunately, untreated TR
negatively influences functional status and long-term
survival,9 and late surgical intervention for recurrent TR
is often prohibitively dangerous.10,23,24 Recent studies
have demonstrated both an improvement in NYHA
functional class8 as well as a survival benefit25 in patients
who undergo concomitant tricuspid annuloplasty at the
time of mitral valve surgery compared with those who do
not. As such, there has been increasing support for a more
liberal application of tricuspid valve repair in patients
with coexistent TR who present for mitral valve surgery.
However the question remains, who should undergo
concomitant tricuspid repair?
The American College of Cardiology and American
Heart Association have taken a more aggressive approach
in the most recent update on the management of valvular
heart disease. Current guidelines now advise concomitant
tricuspid valve repair at the time of mitral valve surgery if
coexistent TR is severe (class I), and suggest repair if TR
is less than severe in patients with tricuspid annular dilation
or pulmonary hypertension (class IIa).17 The 2012 iteration
of European guidelines is similar to that of the United
States, assigning a class IIa recommendation to tricuspid
repair in patients undergoing any left-sided valve surgery
with mild or moderate coexistent TR if the annulus is>40
mm or>21 mm/m2 (albeit all level of evidence C).18 Yet,
absent from all guidelines is an emphasis on diseaseThe Journal of Thoracic and Caretiology. A uniform approach to functional TR assumes
that TR progresses similarly after correction of all types
of left-sided valve dysfunction.
Etiologies of mitral valve disease are quite distinct
and convey disparate prognoses. For example, the left
ventricular dysfunction observed in ischemic and nonische-
mic cardiomyopathy may commonly compromise right
ventricular function, leading to significant tricuspid annular
dilation and TR. Repair of ischemicMR is also significantly
less effective than that of MR due to leaflet prolapse.
Similarly, mitral valve repair of rheumatic valve disease
does not halt the continued valvulopathic processes that
underlie the disease. In such patients, the development of
late recurrent TR is quite common. In fact, in the
setting of ischemic or rheumatic mitral valve disease,
clinically significant late TR has been shown to develop
in 37% to 49% of patients.6,7 Even more striking,
Matsunaga and Duran7 documented rapid progression to
greater-than-moderate TR in 74% of patients just 3 years
after surgery.
To date few studies have examined the natural history and
clinical influence of coexistent TR in those with the most
frequent mitral valve condition encountered in developed
nations—degenerative mitral valve disease.2,12 In an
analysis of 696 patients with mitral valve prolapse and
clinically silent functional TR undergoing isolated mitral
valve repair, Yilmaz and colleagues2 found that clinically
important TR progression is unlikely to occur after mitral
valve repair. Thus, they argue that concomitant surgical
tricuspid intervention for functional TR is rarely necessary
in patients undergoing isolated mitral valve repair for leafletdiovascular Surgery c Volume 148, Number 6 2805
TABLE 2. Risk factors for development of grade 3 to 4 tricuspid
regurgitation
Variable
Univariate Multivariable
Hazard
ratio
P
value
Hazard
ratio
P
value
Demographic
Age 1.1 <.001 1.1 <.001
Gender (female:male) 1.8 .048
Body mass index 0.9 .099
Comorbidities
Previous atrial fibrillation 2.3 .049
Pulmonary hypertension* 0.3 .088
Renal failure 2.3 .415
Hypertension 1.3 .408
Diabetes 1.0 .989
Dyslipidemia 1.1 .697
Chronic lung disease 1.8 .335
Peripheral arterial disease 4.8 .031
Cerebrovascular disease 0.9 .952
Previous cardiac intervention 3.2 .005
Recent congestive heart failure
exacerbation
1.9 .042
New York Heart Association
functional class (vs class I)
.016
II 1.4
III 1.8
IV 28.6
Mean pulmonary artery pressure 1.0 .779
Ejection fraction 1.0 .324
Tricuspid regurgitation grade
(vs grade 0)
.001 .006
1 1.3 1.4
2 3.4 3.4
3 4.5 3.1
Tricuspid annular diameter 1.0 .964
Indexed tricuspid annular diameter 6.1 .020
Leaflet prolapse (vs posterior) .213
Anterior 1.2
Bileaflet 2.1
Right minithoracotomy approach 0.9 .667
*Pulmonary hypertension defined as mean pulmonary artery pressure  25 mm Hg.
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5 years after surgery, the mean TR grade remained only
mild. Yet, an average may not be the ideal method for
analyzing ordinal data, particularly for a semiquantitative
variable like TR grade. When presented as a proportion,
nearly 30% of patients exhibited grade 3 or greater TR after
5 years of follow-up.2 However, recurrent TR did not
negatively influence survival and only 1 patient required
reoperation for severe symptomatic TR.
We also examined a homogenous population of patients
undergoing isolated mitral valve surgery for degenerative
MR. Recurrent TR was not uncommon—36% of patients
were estimated to have moderate or greater TR 9 years
after surgery. Nevertheless, development of significant TR2806 The Journal of Thoracic and Cardiovascular Surduring follow-up did not influence survival or NYHA
functional class. Because patients with degenerative mitral
valve disease are increasingly referred for surgery earlier in
the disease process, it is not surprising that overall survival
was excellent. Accordingly a tremendous number of
patients would be necessary to power a study to detect
significant differences in survival. Furthermore, NYHA
functional class is not an ideal metric for symptoms due
to right heart failure from untreated TR. Although no
patient underwent reoperation for significant TR, patients
with higher postoperative TR grades more frequently
had significant right ventricular dysfunction during the
follow-up period. Desai and colleagues12 demonstrated
the bidirectional interrelatedness of TR and right ventricu-
lar function: not only does right ventricular dysfunction
affect severity of TR, but also reduced TR is associated
with improved right ventricular function. Tricuspid valve
repair remains the most effective treatment to improve
right ventricular function.26 Thus, right ventricular
function may be a better metric than NYHA functional
class in this population. In fact, European guidelines now
advise physicians to consider tricuspid valve repair in
asymptomatic patients with worsening right ventricular
function.18
Only 2 preoperative variables were identified as
independent risk factors for TR progression in the overall
cohort: increasing age and preoperative TR grade. In
addition to those risk factors, prior investigations have
documented female gender,2,6 atrial fibrillation,2,27
enlarged left atrium,27 pulmonary hypertension,28 tricuspid
annular dilation,8,29,30 and diabetes mellitus2 to be indepen-
dently associated with the development of late TR after
left-sided valve surgery. Although a preoperative history
of atrial arrhythmias was a significant univariate predictor
of TR progression, in our study it failed to prove significant
in the multivariable model. On the other hand, postoperative
atrial fibrillation was a significant risk factor for TR
progression in multivariable analysis, and thus in such
patients all efforts should be made to try and maintain sinus
rhythm after surgery. Interstudy differences in the risk
factors identified may be a product of patient selection,
because many studies have included aortic valve surgery
and/or mixed etiologies of mitral valve disease. However,
it may also allude to the multifactorial nature of functional
TR.28
It should also be noted that intraoperative echocardio-
graphic assessment of TR does not correlate with
preoperative TR grade and is not indicative of the risk of
developing late TR. Afterload reduction from general
anesthesia as well as volume unloading before surgery
typically reduce the severity of TR noted in the operating
theater. As such, surgical decision making should largely
be based on preoperative imaging. In fact, preoperative
TR grade strongly predicted development of late TR in agery c December 2014
FIGURE 3. Freedom from developing moderate or severe right ventricular (RV) dysfunction after isolated mitral valve surgery stratified by development of
significant postoperative tricuspid regurgitation.
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toward intervening on nonsevere grades of TR.
In our study population, tricuspid annular dimensions
were larger in patients with higher grades of preoperative
TR. In fact, all but 1 patient with grade 3 TR preoperatively
had a tricuspid annular diameter above the recommended
threshold for intervention, and it was this population that
had the greatest risk for developing late TR. Thus, once a
valve has been geometrically altered enough to permit
moderate grades of TR, it is unlikely that the valve will
structurally remodel enough after mitral valve repair to
prevent progressive or recurrent TR. Although preoperative
grade of TR was a stronger predictor of developing late TR
in the overall study cohort, when the analysis was limited to
patients with less than grade 3 TR, indexed tricuspid
annular diameter remained the only significant risk factor
for developing significant postoperative TR. Thus, it may
be advised to intervene on the tricuspid valve in the setting
of mild or absent TR when the indexed tricuspid annular
diameter is enlarged. Furthermore, it is important to note
that nonindexed tricuspid annular diameter was not a
significant risk factor for progression of TR on univariate
or multivariable analysis. This lack of predictive power
may be due to the fact that nonindexed parameters do not
account for relatively dilated annuli in smaller people.
Given that uncorrected chronic MR often results in
progressive left ventricular dysfunction, pulmonary
hypertension, and atrial fibrillation (all common risk factors
for late TR), it was of interest to elucidate if asymptomatic
individuals are less likely to develop recurrent TR. AlthoughThe Journal of Thoracic and Carsignificant on univariate analysis, preoperative NYHA func-
tional class failed to predict progressive postoperative TR on
multivariable analysis. Thus, preoperative symptom status
may be a confounder for more important variables—already
having evidence of TR seems to be a much stronger predic-
tor of whether patients are likely to develop recurrent TR af-
ter left-sided valve surgery.
We believe that our results are in accord with the updated
American and European guidelines, in that patients with
only mild or moderate coexistent TR (and even those
without any evidence of preoperative TR) are at increased
risk of developing late functional TR, especially in the
setting of tricuspid annular enlargement. Although rates
of TR progression appear to be less severe in patients
with degenerative mitral valve disease than other etiologies,
the risk of developing TR with concomitant right ventricu-
lar dysfunction is significant. Given the low incremental
risk of concomitant tricuspid annuloplasty, a more liberal
strategy of tricuspid valve repair may prove beneficial—
wherein all patients with moderate TR undergo tricuspid
valve repair, and patients with mild or absent TR may
undergo concomitant preventative annuloplasty when there
is enlargement of the indexed tricuspid annular diameter.Limitations
The limitations of our study include its retrospective
methodology and associated biases. Of course, treatment
allocation bias exists in that the decision to intervene on
the tricuspid valve at the time of mitral valve surgery was
at the discretion of the surgeon. Comparing our study cohortdiovascular Surgery c Volume 148, Number 6 2807
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intervention would be valuable, but our limited experience
with such patients (N ¼ 37) limits a feasible evaluation.
Because echocardiographic follow-up was incomplete, we
recognize the potential for under- or overestimation of the
incidence of recurrent symptomatic severe TR. Also,
because multiple postoperative echocardiograms were
unavailable for each patient, we were unable to perform a
mixed modeling analysis.31 However as in most studies,
TR appears to progress over time, so it is possible that
having access to echocardiograms at multiple time points
may have hastened the observed rate of progression to grade
3 to 4 TR. Furthermore, we acknowledge that we are unable
to quantify symptoms of right heart failure and have used
NYHA functional class and echocardiographic assessment
of right ventricular function as surrogate measures. Because
the study occurred over a decade, practice patterns may
have changed as well as the ability to quantify TR via
echocardiography.
CONCLUSIONS
Despite durable correction of degenerative MR, less-
than-severe TR and even absent TR is likely to progress
after surgery for degenerative MR if uncorrected. Although
uncorrected TR does not appear to negatively influence
survival in this population, it is associated with impaired
right ventricular function. Given the low incremental risk
of tricuspid annuloplasty, a more aggressive strategy of
concomitant tricuspid repair may be warranted. However
disease etiology and specific preoperative risk factors
should be considered for appropriate patient selection.
Clearly additional investigation is necessary to best inform
clinical decisionmaking in the management of this complex
disease process, and hopefully a randomized clinical trial
will be conducted in the near future.
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so at 10 years there is a standard deviation of about 14%.
Our data are fairly similar and go along with the other largeA
C
DDrKenton J. Zehr (Baltimore, Md). I thank the Association for
the opportunity to discuss the manuscript, and I thank you,
Dr Goldstone, for a copy well in advance of the meeting. I have
no disclosures.
I applaud the University of Pennsylvania group in helping us to
understand the fate of mitral valve repair for various pathologies
over the past many years. Their series is large enough to provide
a clue into the effect on the right side of the heart.
Of your series of more than 4000 patients, your included cohort
was only 10% of the total group, and of these, only 43% had grade
1 to 3 tricuspid regurgitation (TR). This seems like a small number
according to the total group of 4000 patients. Was your exclusion
criteria too aggressive?
Dr Goldstone. That is an excellent question. The 4200 patients
were all-comers for mitral valve surgery, including any other
concomitant procedure, such as a root replacement. One thousand
patients had isolated mitral valve surgery, but that did include
concomitant atrial ablation.
Because of the potential influence of atrial fibrillation on TR
progression, and because recent studies have shown differences
in etiology of mitral disease affecting progression of TR, we
limited our study population to patients with degenerative mitral
valve disease who underwent isolated mitral valve surgery,
excluding patients with concomitant atrial ablations. That is why
we ended up with 500 patients.
This was the particular patient cohort I wanted to look at
because the most recent studies in patients with degenerative
mitral valve disease argued against concomitant tricuspid
annuloplasty, but our guidelines do not distinguish between
disease etiology, and I think that is something that we need more
data on moving forward.
Dr Zehr. The median follow-up time was 3.4 years. So this
really is an intermediate-term follow-up study. Although you
reported 10-year freedom from TR at 63%, there were only 7
patients at risk at that time point. So if you back up and look at
the 5-year follow-up, the freedom from significant TR was 90%,
which I would determine to be an excellent result.
So if you look at the data in a different way at an intermediate
follow-up, the TR increase was relatively inconsequential with
regard to symptoms and by grade. There is really only a 1.5+
overall increase in patients with grade 0 to 2+ preop, and indeed,
among the 37 patients that had +3 preop, they actually got better
over time at intermediate follow-up. No additional valve work is
without risk, and tricuspid annuloplasty carries a small risk of
increased need for pacemaker and an increased risk of
endocarditis.The Journal of Thoracic and CarShould the conclusion be the opposite? That is, in patients with
degenerative disease, the tricuspid valve should be left alone?
Is this TR clinically relevant?
Dr Goldstone. That is a very good point and I think our
conclusions are slightly controversial, but this is a controversial
topic.
In terms of the midterm study, I agree, our median follow-up
was 3.5 years, but that is why we conducted actuarial analyses,
which demonstrate the overall trend. At the longest follow-up,
more than 10 years after surgery, freedom frommoderate or severe
TR would be estimated to be 64%. But the error bars do increase,
studies in patients with degenerative mitral valve disease, such
as that by Yilmaz and colleagues as well as the Cleveland Clinic
study. Although the Mayo Clinic argued that nonsevere functional
TR is unlikely to progress in these patients, they did use the mean
grade of TR. Taking the mean of an ordinal variable can be
misleading, especially because such data may be skewed. The
authors did include a table that showed that at 5 years after surgery,
30% of patients had grade 3 or 4 TR, which is similar to the trend in
our population. I believe the Cleveland Clinic data showed a
similar trend, and actually at 3 years after surgery the patients
with more significant preoperative TRwho did not have a tricuspid
valve repair already recurred to their prior grade of TR. In terms of
the patients with moderate preoperative TR, they also seem to
progress more quickly to recurrent moderate TR.
Dr Zehr. Seventy-three percent were reported to have
follow-up echos. Do we know what happened to the other 27%
of patients? Were they happy and healthy and thus no need for
an echo or were they lost to follow-up?
Dr Goldstone. They were lost to follow-up.
Dr Steven F. Bolling (Ann Arbor, Mich). This is a very nice
series in a controversial area. In light of the Dreyfus paper that
shows that the addition of a tricuspid annuloplasty at the time of
a mitral does not add to the operative mortality and in light of
the Calafiore paper that says that the operative mortality may
actually go down with the addition of a tricuspid annuloplasty in
those patients, we applaud your aggressive approach.
In the real world, do you do a preventative tricuspid
annuloplasty? What is your criteria now to do an annuloplasty
while you are there?
Dr Goldstone. We just came across these data at this meeting.
The reason we do not have a comparison group is because
currently at our institution wewill repair the tricuspid valve if there
is concomitant severe TR. So our comparison group would have
been only about 30 patients and they would have all had severe
preoperative TR.
Dr Woo is going to become more aggressive with performing
concomitant tricuspid annuloplasty in patients with a dilated
tricuspid annulus who are undergoing mitral valve surgery.
Dr Bolling. In light of those data, do you think this calls for a
randomized, large prospective trial in this group of patients?
Dr Goldstone. I have been trying to come up with a good
way to conduct a randomized controlled trial in this group of pa-
tients for quite some time. The main issue that we run into is
selecting a satisfiable clinical end point. First of all, the trial
would need to be fairly long depending on what type of mitral
valve disease etiology is selected in the study. Progression of TRdiovascular Surgery c Volume 148, Number 6 2809
Acquired Cardiovascular Disease Goldstone et al
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Dis definitely faster in patients with functional or ischemic mitral
regurgitation, and I think that has to do with concomitant right
ventricular dysfunction in those patients versus a patient with
mitral valve prolapse. But you are still going to have to create
a study that spans many years, as well as choose an appropriate
clinical end point. Unfortunately, in my opinion New York Heart
Association functional class is a poor metric for right heart
function. I did not have data on diuretic use, liver transaminases,
or kidney function. I believe that in a clinical trial a surrogate end
point, such as right ventricular dimensions or function in addition
to grade of tricuspid regurgitation, would need to be used.
However I definitely agree that a randomized prospective trial
would be ideal to help inform the cardiac surgery community on
this controversial issue.
Dr Harold L. Lazar (Boston, Mass). Did you measure
pulmonary artery (PA) pressures either by echo or by cath and
have you found that to be a determinant of what ultimately happensEDITORIAL CO
See related article on pages 2802-10.
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2810 The Journal of Thoracic and Cardiovascular Surto the TR? I have seen that patients who have minimal TR but have
high PA pressures at the time of mitral valve replacement or
repair tend to be the ones who tend to have increased TR in the
future.
Dr Goldstone. We did look at PA pressures. They were
measured by right heart catheterization, and preoperative mean
PA pressure was not a significant predictor of progression of TR
postoperatively in univariate analysis. That is consistent with the
Mayo paper, which did not find pulmonary artery pressure to be
a significant predictor either. I agree that it makes sense that
pulmonary hypertension would influence TR progression.
Perhaps the reason why different studies identify different
predictors of TR progression alludes to the multifactorial nature
of functional TR.
Dr Lazar. In those patients who had progressive TR, did their
PA pressures go up or did they stay the same?
Dr Goldstone. I do not have longitudinal data on PA pressure.MMENTARYThe role of cognitive dissonance in the management of functional
tricuspid regurgitation at the time of degenerative mitral valve repairRakesh M. Suri, MD, DPhil,a and Yan Topilsky, MDbCognitive dissonance: Psychologic conflict resulting
from incongruous beliefs and attitudes held
simultaneously.
In this issue of the Journal, Goldstone and colleagues1
from the University of Pennsylvania and Stanford have
assembled the third largest series (n¼ 495) in the literature
of patients with mitral valve prolapse undergoing mitral
valve repair with coexistent functional tricuspid valve
regurgitation (TR) not surgically managed. Forty-three
percent of patients had anywhere between trivial to
moderately severe TR at mitral valve repair, and freedomfrom greater than moderate TR was approximately 60%
at 9 years. Older age and grade of preoperative TR pre-
dicted progression; and ‘‘some degree’’ of right ventricular
dysfunction was more frequent in those with severe TR
during follow-up.
What does this study tell us? The findings reaffirm those
published from the Mayo Clinic in 2011 and in 2014.2,3 Our
institution’s first series studied 699 patients who underwent
mitral valve repair for isolated degenerative leaflet prolapse
and moderate or less coexistent functional TR. We
identified that moderate TR actually regressed with time
in most cases after successful and durable repair of
degenerative mitral valve disease. Indeed, only 1 patient
out of the entire series required reoperation for
progressive TR 4.5 years after mitral valve repair. Our
most recent report expanded on this analysis, studying
747 adult patients with mitral valve prolapse among
whom 683 underwent mitral valve repair and 64 had
replacement. We found no difference in the occurrence of
moderately severe or severe TR after mitral valve repair
versus replacement and found the univariate predictors of
TR progression to be older age, female sex, higher
pulmonary arterial pressure, and larger left atrial size.
Only 2 patients required reoperation for late functional
TR. The report of Goldstone and colleagues1 thus adds togery c December 2014
